Laura Saba
Concepts (705)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carotid Stenosis | 8 | 2020 | 107 | 3.320 |
Why?
| | Plaque, Atherosclerotic | 4 | 2020 | 61 | 2.240 |
Why?
| | Alcohol Drinking | 18 | 2021 | 837 | 1.790 |
Why?
| | Quantitative Trait Loci | 25 | 2025 | 378 | 1.720 |
Why?
| | Carotid Arteries | 5 | 2020 | 208 | 1.520 |
Why?
| | Transcriptome | 10 | 2025 | 1038 | 1.340 |
Why?
| | Adrenocortical Carcinoma | 8 | 2026 | 72 | 1.330 |
Why?
| | Ethanol | 16 | 2024 | 631 | 1.300 |
Why?
| | Brain | 23 | 2026 | 2947 | 1.270 |
Why?
| | Adrenal Cortex Neoplasms | 7 | 2026 | 70 | 1.210 |
Why?
| | Gene Regulatory Networks | 7 | 2023 | 317 | 1.180 |
Why?
| | High-Throughput Nucleotide Sequencing | 7 | 2024 | 530 | 1.050 |
Why?
| | Magnetic Resonance Imaging, Cine | 2 | 2025 | 214 | 1.010 |
Why?
| | Quantitative Trait, Heritable | 7 | 2017 | 113 | 0.990 |
Why?
| | Gene Expression Profiling | 16 | 2021 | 1767 | 0.960 |
Why?
| | Magnetic Resonance Imaging | 7 | 2025 | 3904 | 0.890 |
Why?
| | Rats, Inbred Strains | 7 | 2019 | 321 | 0.890 |
Why?
| | Mitotane | 6 | 2025 | 10 | 0.840 |
Why?
| | Systems Biology | 3 | 2021 | 69 | 0.830 |
Why?
| | Myocarditis | 1 | 2025 | 102 | 0.830 |
Why?
| | Rats | 24 | 2026 | 5584 | 0.810 |
Why?
| | Trace Elements | 2 | 2021 | 52 | 0.800 |
Why?
| | Takotsubo Cardiomyopathy | 1 | 2023 | 3 | 0.800 |
Why?
| | Hemorrhage | 2 | 2019 | 822 | 0.770 |
Why?
| | Genetic Predisposition to Disease | 13 | 2024 | 2378 | 0.760 |
Why?
| | Liver | 10 | 2024 | 1896 | 0.740 |
Why?
| | Cerebrovascular Disorders | 2 | 2022 | 104 | 0.730 |
Why?
| | MicroRNAs | 6 | 2019 | 686 | 0.700 |
Why?
| | Atrial Appendage | 1 | 2022 | 36 | 0.690 |
Why?
| | Phenotype | 16 | 2026 | 3155 | 0.680 |
Why?
| | Polymorphism, Single Nucleotide | 18 | 2025 | 2158 | 0.670 |
Why?
| | Sequence Analysis, RNA | 7 | 2022 | 442 | 0.670 |
Why?
| | Animals | 65 | 2026 | 38030 | 0.660 |
Why?
| | Precision Medicine | 1 | 2025 | 459 | 0.660 |
Why?
| | Polyadenylation | 1 | 2021 | 39 | 0.650 |
Why?
| | RNA | 6 | 2021 | 910 | 0.650 |
Why?
| | Protein Carbonylation | 7 | 2019 | 57 | 0.630 |
Why?
| | RNA, Long Noncoding | 2 | 2020 | 172 | 0.630 |
Why?
| | Liver Diseases, Alcoholic | 5 | 2024 | 98 | 0.610 |
Why?
| | Atherosclerosis | 2 | 2021 | 409 | 0.610 |
Why?
| | Mustard Gas | 3 | 2025 | 77 | 0.600 |
Why?
| | Alcoholism | 9 | 2026 | 822 | 0.600 |
Why?
| | Chemical Warfare Agents | 3 | 2025 | 89 | 0.590 |
Why?
| | Adipose Tissue | 2 | 2020 | 645 | 0.570 |
Why?
| | Software | 8 | 2025 | 680 | 0.570 |
Why?
| | Drug Tolerance | 4 | 2020 | 99 | 0.570 |
Why?
| | Cerebral Hemorrhage | 1 | 2019 | 125 | 0.560 |
Why?
| | Male | 80 | 2026 | 72842 | 0.540 |
Why?
| | Tunica Media | 1 | 2018 | 37 | 0.540 |
Why?
| | Tunica Intima | 1 | 2018 | 78 | 0.530 |
Why?
| | Genetic Variation | 5 | 2024 | 972 | 0.530 |
Why?
| | Antineoplastic Agents, Hormonal | 5 | 2025 | 193 | 0.520 |
Why?
| | Databases, Genetic | 5 | 2017 | 238 | 0.520 |
Why?
| | Complement C3 | 5 | 2024 | 187 | 0.510 |
Why?
| | Alcohol-Related Disorders | 1 | 2018 | 121 | 0.510 |
Why?
| | Genome-Wide Association Study | 4 | 2026 | 1407 | 0.500 |
Why?
| | Humans | 103 | 2026 | 145474 | 0.500 |
Why?
| | Middle Aged | 46 | 2025 | 36215 | 0.490 |
Why?
| | Dexamethasone | 4 | 2025 | 365 | 0.490 |
Why?
| | Tomography, X-Ray Computed | 8 | 2021 | 2769 | 0.490 |
Why?
| | Female | 75 | 2026 | 78844 | 0.470 |
Why?
| | Genomics | 6 | 2024 | 825 | 0.460 |
Why?
| | beta-Thalassemia | 5 | 2025 | 40 | 0.460 |
Why?
| | Brain Ischemia | 1 | 2019 | 359 | 0.460 |
Why?
| | Central Nervous System Depressants | 4 | 2010 | 84 | 0.450 |
Why?
| | Aged | 30 | 2024 | 26153 | 0.430 |
Why?
| | Endoplasmic Reticulum Stress | 2 | 2026 | 118 | 0.420 |
Why?
| | Angiography | 4 | 2010 | 208 | 0.420 |
Why?
| | Retrospective Studies | 19 | 2025 | 17291 | 0.420 |
Why?
| | Computed Tomography Angiography | 3 | 2021 | 146 | 0.420 |
Why?
| | Corneal Injuries | 2 | 2025 | 42 | 0.410 |
Why?
| | Models, Statistical | 1 | 2018 | 671 | 0.410 |
Why?
| | Aged, 80 and over | 13 | 2024 | 8333 | 0.390 |
Why?
| | Internet | 6 | 2010 | 689 | 0.380 |
Why?
| | Oligonucleotide Array Sequence Analysis | 6 | 2019 | 749 | 0.380 |
Why?
| | Complement Activation | 4 | 2025 | 399 | 0.380 |
Why?
| | Mice | 34 | 2025 | 18329 | 0.370 |
Why?
| | Bayes Theorem | 5 | 2020 | 420 | 0.370 |
Why?
| | Complement Inactivating Agents | 2 | 2025 | 74 | 0.360 |
Why?
| | Severity of Illness Index | 5 | 2021 | 2930 | 0.360 |
Why?
| | Genome | 4 | 2024 | 305 | 0.340 |
Why?
| | Adult | 43 | 2025 | 40777 | 0.330 |
Why?
| | Oxidative Stress | 7 | 2026 | 1356 | 0.330 |
Why?
| | Heart Ventricles | 2 | 2026 | 756 | 0.330 |
Why?
| | Ultrasonography | 3 | 2020 | 785 | 0.330 |
Why?
| | Aldehydes | 5 | 2019 | 139 | 0.330 |
Why?
| | Glutathione Transferase | 4 | 2019 | 92 | 0.320 |
Why?
| | Mice, Inbred Strains | 9 | 2020 | 396 | 0.310 |
Why?
| | Health Education | 3 | 2008 | 346 | 0.300 |
Why?
| | ROC Curve | 4 | 2019 | 617 | 0.290 |
Why?
| | Endometriosis | 2 | 2020 | 58 | 0.290 |
Why?
| | Rats, Wistar | 3 | 2020 | 450 | 0.290 |
Why?
| | Carotid Artery Diseases | 1 | 2009 | 70 | 0.290 |
Why?
| | Genetic Association Studies | 5 | 2017 | 369 | 0.290 |
Why?
| | Oxycodone | 2 | 2026 | 52 | 0.280 |
Why?
| | Tomography, Spiral Computed | 1 | 2008 | 30 | 0.280 |
Why?
| | Synaptic Transmission | 1 | 2010 | 292 | 0.280 |
Why?
| | Models, Genetic | 6 | 2025 | 524 | 0.270 |
Why?
| | Apoptosis | 4 | 2026 | 2440 | 0.270 |
Why?
| | Brain Diseases | 1 | 2009 | 155 | 0.270 |
Why?
| | Nanoparticles | 4 | 2025 | 517 | 0.260 |
Why?
| | Gastrointestinal Microbiome | 2 | 2026 | 767 | 0.260 |
Why?
| | Cornea | 2 | 2025 | 154 | 0.250 |
Why?
| | Genotype | 11 | 2025 | 1852 | 0.250 |
Why?
| | Tandem Mass Spectrometry | 5 | 2024 | 572 | 0.250 |
Why?
| | Point Mutation | 2 | 2001 | 240 | 0.250 |
Why?
| | Propidium | 1 | 2026 | 8 | 0.250 |
Why?
| | Annexin A5 | 1 | 2026 | 23 | 0.250 |
Why?
| | Polyploidy | 1 | 2026 | 14 | 0.240 |
Why?
| | Contrast Media | 5 | 2021 | 497 | 0.240 |
Why?
| | Genes, Regulator | 1 | 2006 | 35 | 0.240 |
Why?
| | Genetic Background | 1 | 2026 | 16 | 0.240 |
Why?
| | Receptors, GABA-A | 3 | 2026 | 137 | 0.240 |
Why?
| | Breast Neoplasms | 6 | 2023 | 2382 | 0.240 |
Why?
| | Triterpenes | 1 | 2026 | 27 | 0.230 |
Why?
| | Adenylyl Cyclases | 3 | 2012 | 60 | 0.230 |
Why?
| | Gene Expression Regulation | 8 | 2025 | 2597 | 0.230 |
Why?
| | PTEN Phosphohydrolase | 2 | 2018 | 165 | 0.230 |
Why?
| | Smoking Prevention | 1 | 2006 | 166 | 0.230 |
Why?
| | Necrosis | 1 | 2026 | 244 | 0.230 |
Why?
| | Microfilament Proteins | 1 | 2026 | 135 | 0.220 |
Why?
| | Activating Transcription Factor 3 | 1 | 2025 | 4 | 0.220 |
Why?
| | Rats, Inbred SHR | 4 | 2018 | 36 | 0.220 |
Why?
| | Activating Transcription Factor 4 | 1 | 2025 | 22 | 0.220 |
Why?
| | Limbus Corneae | 1 | 2025 | 8 | 0.220 |
Why?
| | Iron | 2 | 2021 | 357 | 0.220 |
Why?
| | Phytochemicals | 1 | 2025 | 13 | 0.220 |
Why?
| | Recombination, Genetic | 2 | 2017 | 203 | 0.220 |
Why?
| | Tea | 1 | 2025 | 17 | 0.220 |
Why?
| | Nanomedicine | 1 | 2025 | 47 | 0.220 |
Why?
| | Hypothalamo-Hypophyseal System | 4 | 2017 | 199 | 0.220 |
Why?
| | Signal Transduction | 10 | 2026 | 5216 | 0.210 |
Why?
| | Polyethylene Glycols | 3 | 2025 | 649 | 0.210 |
Why?
| | Mice, Inbred C57BL | 12 | 2025 | 5983 | 0.210 |
Why?
| | Pituitary-Adrenal System | 3 | 2017 | 164 | 0.210 |
Why?
| | Endarterectomy, Carotid | 2 | 2017 | 64 | 0.200 |
Why?
| | Heart Transplantation | 2 | 2021 | 680 | 0.200 |
Why?
| | Doxorubicin | 3 | 2025 | 401 | 0.200 |
Why?
| | Stents | 1 | 2008 | 564 | 0.200 |
Why?
| | Algorithms | 4 | 2023 | 1845 | 0.200 |
Why?
| | Magnesium | 2 | 2021 | 156 | 0.200 |
Why?
| | Analgesics, Opioid | 3 | 2026 | 1149 | 0.200 |
Why?
| | Base Sequence | 6 | 2021 | 2170 | 0.200 |
Why?
| | Cysteine | 1 | 2024 | 211 | 0.190 |
Why?
| | Gastrointestinal Tract | 1 | 2026 | 204 | 0.190 |
Why?
| | Germ-Line Mutation | 1 | 2024 | 176 | 0.190 |
Why?
| | Diastole | 1 | 2023 | 146 | 0.190 |
Why?
| | Analgesia | 1 | 2024 | 106 | 0.190 |
Why?
| | Sensitivity and Specificity | 4 | 2019 | 1997 | 0.190 |
Why?
| | Immunoglobulins | 2 | 2024 | 162 | 0.190 |
Why?
| | Rats, Inbred BN | 3 | 2018 | 56 | 0.180 |
Why?
| | Lysine | 1 | 2024 | 305 | 0.180 |
Why?
| | Dextrans | 2 | 2024 | 84 | 0.180 |
Why?
| | Acute Disease | 1 | 2025 | 1036 | 0.180 |
Why?
| | Whole Genome Sequencing | 2 | 2024 | 177 | 0.180 |
Why?
| | Phosphorus | 2 | 2021 | 90 | 0.180 |
Why?
| | Immunoconjugates | 1 | 2023 | 138 | 0.180 |
Why?
| | Fetal Development | 2 | 2022 | 298 | 0.180 |
Why?
| | Behavior, Addictive | 2 | 2020 | 88 | 0.170 |
Why?
| | Multifactorial Inheritance | 2 | 2025 | 195 | 0.170 |
Why?
| | Leukopenia | 1 | 2021 | 33 | 0.170 |
Why?
| | Hepatocyte Nuclear Factor 1-alpha | 1 | 2021 | 21 | 0.170 |
Why?
| | Myocytes, Cardiac | 1 | 2026 | 546 | 0.170 |
Why?
| | Proteome | 3 | 2024 | 514 | 0.170 |
Why?
| | Anti-Inflammatory Agents | 1 | 2025 | 477 | 0.170 |
Why?
| | Heart Atria | 1 | 2022 | 141 | 0.170 |
Why?
| | Magnesium Deficiency | 1 | 2020 | 2 | 0.170 |
Why?
| | Chromatography, Liquid | 5 | 2024 | 450 | 0.170 |
Why?
| | Selenium | 1 | 2021 | 50 | 0.170 |
Why?
| | Myocardium | 2 | 2018 | 934 | 0.160 |
Why?
| | Antibiotics, Antineoplastic | 2 | 2021 | 140 | 0.160 |
Why?
| | Mycophenolic Acid | 1 | 2021 | 120 | 0.160 |
Why?
| | Matrix Metalloproteinases | 1 | 2021 | 95 | 0.160 |
Why?
| | Protein Processing, Post-Translational | 3 | 2024 | 471 | 0.160 |
Why?
| | Hydroxycholesterols | 1 | 2020 | 5 | 0.160 |
Why?
| | Copper | 1 | 2021 | 119 | 0.160 |
Why?
| | Stem Cells | 1 | 2025 | 628 | 0.160 |
Why?
| | Echocardiography | 1 | 2023 | 647 | 0.160 |
Why?
| | alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid | 1 | 2020 | 15 | 0.160 |
Why?
| | Complement System Proteins | 2 | 2024 | 314 | 0.160 |
Why?
| | Iron Overload | 2 | 2025 | 19 | 0.150 |
Why?
| | Sigmoid Diseases | 1 | 2020 | 14 | 0.150 |
Why?
| | Rectal Diseases | 1 | 2020 | 24 | 0.150 |
Why?
| | Nicotinamide Mononucleotide | 1 | 2019 | 9 | 0.150 |
Why?
| | Hydrocarbons, Chlorinated | 1 | 2019 | 21 | 0.150 |
Why?
| | Osteoprotegerin | 3 | 2009 | 22 | 0.150 |
Why?
| | Risk | 2 | 2021 | 919 | 0.150 |
Why?
| | Epithelium, Corneal | 1 | 2019 | 41 | 0.150 |
Why?
| | User-Computer Interface | 1 | 2020 | 165 | 0.150 |
Why?
| | Rabbits | 3 | 2025 | 652 | 0.150 |
Why?
| | Genetic Markers | 1 | 2020 | 335 | 0.150 |
Why?
| | Pancreatic Diseases | 1 | 2020 | 66 | 0.150 |
Why?
| | Pesticides | 1 | 2019 | 59 | 0.150 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2022 | 627 | 0.150 |
Why?
| | Anthracenes | 1 | 2019 | 31 | 0.150 |
Why?
| | Gene Expression | 3 | 2014 | 1476 | 0.150 |
Why?
| | Drosophila | 1 | 2020 | 164 | 0.150 |
Why?
| | Reflex, Righting | 2 | 2018 | 15 | 0.150 |
Why?
| | Mice, Inbred DBA | 5 | 2019 | 182 | 0.150 |
Why?
| | Opsonin Proteins | 1 | 2019 | 19 | 0.140 |
Why?
| | Protein Corona | 1 | 2019 | 9 | 0.140 |
Why?
| | Acylation | 1 | 2019 | 30 | 0.140 |
Why?
| | Cushing Syndrome | 2 | 2010 | 10 | 0.140 |
Why?
| | Fluorenes | 1 | 2019 | 45 | 0.140 |
Why?
| | Liposomes | 2 | 2019 | 262 | 0.140 |
Why?
| | Eicosanoids | 1 | 2019 | 58 | 0.140 |
Why?
| | Biomarkers | 7 | 2020 | 4295 | 0.140 |
Why?
| | Chimera | 1 | 2019 | 61 | 0.140 |
Why?
| | Pharmaceutical Preparations | 1 | 2020 | 170 | 0.140 |
Why?
| | Learning Curve | 1 | 2019 | 71 | 0.140 |
Why?
| | Antioxidants | 2 | 2019 | 550 | 0.140 |
Why?
| | Drosophila Proteins | 1 | 2020 | 213 | 0.140 |
Why?
| | Steroid 11-beta-Hydroxylase | 1 | 2018 | 2 | 0.140 |
Why?
| | Pulmonary Embolism | 1 | 2021 | 241 | 0.140 |
Why?
| | Reproducibility of Results | 3 | 2022 | 3413 | 0.140 |
Why?
| | Antineoplastic Agents | 2 | 2026 | 2214 | 0.140 |
Why?
| | Lymphocytes | 1 | 2020 | 376 | 0.140 |
Why?
| | Sex Characteristics | 4 | 2021 | 782 | 0.140 |
Why?
| | Metabolic Clearance Rate | 1 | 2018 | 115 | 0.140 |
Why?
| | Unsupervised Machine Learning | 1 | 2018 | 23 | 0.140 |
Why?
| | Cell Degranulation | 1 | 2018 | 40 | 0.140 |
Why?
| | Proton Pump Inhibitors | 1 | 2019 | 109 | 0.140 |
Why?
| | Hallucinogens | 1 | 2020 | 111 | 0.140 |
Why?
| | Alveolar Epithelial Cells | 1 | 2019 | 121 | 0.140 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2021 | 273 | 0.140 |
Why?
| | Angiography, Digital Subtraction | 1 | 2018 | 48 | 0.130 |
Why?
| | Zinc | 1 | 2021 | 306 | 0.130 |
Why?
| | Smoking | 2 | 2020 | 1472 | 0.130 |
Why?
| | Silver | 1 | 2018 | 36 | 0.130 |
Why?
| | Hippocampus | 2 | 2022 | 971 | 0.130 |
Why?
| | Gene Knockout Techniques | 1 | 2018 | 119 | 0.130 |
Why?
| | Receptors, Nicotinic | 1 | 2020 | 327 | 0.130 |
Why?
| | Food Preferences | 2 | 2009 | 126 | 0.130 |
Why?
| | Ferrosoferric Oxide | 1 | 2017 | 25 | 0.130 |
Why?
| | Graft Rejection | 1 | 2021 | 521 | 0.130 |
Why?
| | Lung | 2 | 2021 | 4106 | 0.130 |
Why?
| | Hepatitis | 1 | 2017 | 43 | 0.130 |
Why?
| | Feasibility Studies | 1 | 2022 | 1111 | 0.130 |
Why?
| | NF-E2-Related Factor 2 | 1 | 2018 | 101 | 0.130 |
Why?
| | Monocytes | 1 | 2020 | 539 | 0.130 |
Why?
| | Computational Biology | 3 | 2017 | 669 | 0.130 |
Why?
| | Interleukin-6 | 3 | 2006 | 776 | 0.130 |
Why?
| | Adipose Tissue, Brown | 1 | 2017 | 60 | 0.130 |
Why?
| | Pancreas | 1 | 2020 | 341 | 0.130 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2020 | 269 | 0.130 |
Why?
| | Disease Models, Animal | 7 | 2025 | 4560 | 0.130 |
Why?
| | Web Browser | 1 | 2017 | 12 | 0.130 |
Why?
| | Risk Factors | 6 | 2019 | 10885 | 0.130 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2025 | 1443 | 0.130 |
Why?
| | Models, Animal | 1 | 2019 | 393 | 0.130 |
Why?
| | Lung Diseases, Interstitial | 1 | 2023 | 664 | 0.120 |
Why?
| | Gynecology | 1 | 2019 | 181 | 0.120 |
Why?
| | Globins | 2 | 1997 | 21 | 0.120 |
Why?
| | Cholestasis | 1 | 2019 | 214 | 0.120 |
Why?
| | Lod Score | 1 | 2016 | 62 | 0.120 |
Why?
| | Mast Cells | 1 | 2018 | 147 | 0.120 |
Why?
| | Gene Ontology | 1 | 2016 | 53 | 0.120 |
Why?
| | Pain Threshold | 2 | 2010 | 72 | 0.120 |
Why?
| | Chromosomes, Mammalian | 1 | 2016 | 28 | 0.120 |
Why?
| | Chemical and Drug Induced Liver Injury, Chronic | 1 | 2016 | 11 | 0.120 |
Why?
| | Fatty Liver, Alcoholic | 1 | 2016 | 14 | 0.120 |
Why?
| | Encephalitis, Herpes Simplex | 1 | 2016 | 21 | 0.120 |
Why?
| | End Stage Liver Disease | 1 | 2017 | 95 | 0.120 |
Why?
| | Calcium | 2 | 2021 | 1190 | 0.120 |
Why?
| | Liver Diseases | 1 | 2019 | 305 | 0.120 |
Why?
| | Choice Behavior | 2 | 2014 | 180 | 0.120 |
Why?
| | Cell Line, Tumor | 5 | 2026 | 3542 | 0.120 |
Why?
| | Liver Cirrhosis, Alcoholic | 1 | 2015 | 19 | 0.120 |
Why?
| | Hypnotics and Sedatives | 1 | 2018 | 222 | 0.120 |
Why?
| | von Willebrand Factor | 1 | 2016 | 85 | 0.120 |
Why?
| | Linkage Disequilibrium | 1 | 2016 | 253 | 0.110 |
Why?
| | Mitochondria | 2 | 2021 | 992 | 0.110 |
Why?
| | Consensus | 1 | 2018 | 477 | 0.110 |
Why?
| | beta Karyopherins | 1 | 2015 | 9 | 0.110 |
Why?
| | Opioid-Related Disorders | 1 | 2024 | 602 | 0.110 |
Why?
| | Seizures | 1 | 2020 | 483 | 0.110 |
Why?
| | Hydrocortisone | 4 | 2012 | 298 | 0.110 |
Why?
| | Databases, Nucleic Acid | 1 | 2015 | 38 | 0.110 |
Why?
| | Receptor, Serotonin, 5-HT1A | 1 | 2015 | 36 | 0.110 |
Why?
| | Antiviral Agents | 1 | 2021 | 769 | 0.110 |
Why?
| | Herpesvirus 1, Human | 1 | 2016 | 84 | 0.110 |
Why?
| | Anxiety | 1 | 2022 | 1118 | 0.110 |
Why?
| | Immune System | 1 | 2016 | 180 | 0.110 |
Why?
| | Darkness | 1 | 2015 | 26 | 0.110 |
Why?
| | Allergens | 1 | 2018 | 386 | 0.110 |
Why?
| | Pulmonary Artery | 1 | 2021 | 1127 | 0.110 |
Why?
| | Neoplasm Proteins | 1 | 2018 | 441 | 0.110 |
Why?
| | Diet | 3 | 2008 | 1277 | 0.110 |
Why?
| | Circadian Rhythm | 2 | 2020 | 512 | 0.110 |
Why?
| | Peptides | 1 | 2020 | 998 | 0.110 |
Why?
| | Neutrophils | 1 | 2020 | 1124 | 0.110 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2017 | 265 | 0.110 |
Why?
| | Down Syndrome | 1 | 2021 | 525 | 0.100 |
Why?
| | Species Specificity | 4 | 2014 | 546 | 0.100 |
Why?
| | Mammography | 2 | 2006 | 166 | 0.100 |
Why?
| | Cell Proliferation | 2 | 2018 | 2507 | 0.100 |
Why?
| | LDL-Receptor Related Proteins | 1 | 2013 | 6 | 0.100 |
Why?
| | Chloride Channels | 1 | 1993 | 33 | 0.100 |
Why?
| | Oxidation-Reduction | 3 | 2024 | 1067 | 0.100 |
Why?
| | Early Detection of Cancer | 2 | 2023 | 485 | 0.100 |
Why?
| | Proteomics | 4 | 2024 | 1188 | 0.100 |
Why?
| | ErbB Receptors | 1 | 2017 | 635 | 0.100 |
Why?
| | Mitochondrial Proteins | 1 | 2015 | 263 | 0.100 |
Why?
| | Glucocorticoids | 2 | 2009 | 531 | 0.100 |
Why?
| | Chromosome Mapping | 4 | 2020 | 506 | 0.100 |
Why?
| | Epithelial Cells | 1 | 2019 | 1131 | 0.100 |
Why?
| | Genes | 1 | 1993 | 227 | 0.100 |
Why?
| | Database Management Systems | 2 | 2017 | 51 | 0.100 |
Why?
| | Cannabis | 1 | 2020 | 509 | 0.100 |
Why?
| | Blood Pressure | 1 | 2020 | 1779 | 0.100 |
Why?
| | Stroke | 1 | 2022 | 1270 | 0.100 |
Why?
| | Cross-Sectional Studies | 6 | 2025 | 5904 | 0.100 |
Why?
| | Anti-HIV Agents | 1 | 2020 | 912 | 0.090 |
Why?
| | Mice, Knockout | 5 | 2019 | 3124 | 0.090 |
Why?
| | Catalase | 2 | 2017 | 134 | 0.090 |
Why?
| | Exercise | 3 | 2014 | 2198 | 0.090 |
Why?
| | Imaging, Three-Dimensional | 2 | 2015 | 583 | 0.090 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2019 | 1149 | 0.090 |
Why?
| | Feces | 2 | 2026 | 495 | 0.090 |
Why?
| | Dogs | 2 | 2025 | 458 | 0.090 |
Why?
| | DNA Mutational Analysis | 4 | 2001 | 407 | 0.090 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2012 | 92 | 0.090 |
Why?
| | Osteoporosis, Postmenopausal | 1 | 2012 | 41 | 0.090 |
Why?
| | Monoamine Oxidase | 1 | 2011 | 27 | 0.090 |
Why?
| | Follow-Up Studies | 4 | 2021 | 5423 | 0.090 |
Why?
| | Transcription, Genetic | 1 | 2018 | 1454 | 0.090 |
Why?
| | Metabolomics | 3 | 2025 | 732 | 0.090 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2015 | 372 | 0.090 |
Why?
| | Hypertension | 1 | 2020 | 1273 | 0.080 |
Why?
| | Kidney | 1 | 2019 | 1497 | 0.080 |
Why?
| | GTP-Binding Protein beta Subunits | 1 | 2010 | 17 | 0.080 |
Why?
| | Receptors, GABA | 1 | 2010 | 13 | 0.080 |
Why?
| | Rats, Long-Evans | 2 | 2021 | 128 | 0.080 |
Why?
| | Area Under Curve | 3 | 2019 | 331 | 0.080 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 2015 | 429 | 0.080 |
Why?
| | Pituitary-Adrenal Function Tests | 1 | 2010 | 3 | 0.080 |
Why?
| | Bone Density | 2 | 2012 | 487 | 0.080 |
Why?
| | Inflammation | 4 | 2025 | 2878 | 0.080 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2012 | 288 | 0.080 |
Why?
| | Mice, Inbred BALB C | 3 | 2021 | 1261 | 0.080 |
Why?
| | Camptothecin | 2 | 2023 | 138 | 0.080 |
Why?
| | Colonic Diseases, Functional | 2 | 2000 | 3 | 0.080 |
Why?
| | Adaptation, Physiological | 1 | 2014 | 560 | 0.080 |
Why?
| | RNA, Messenger | 5 | 2018 | 2803 | 0.080 |
Why?
| | Adenocarcinoma | 1 | 2017 | 925 | 0.080 |
Why?
| | Postmenopause | 1 | 2012 | 392 | 0.080 |
Why?
| | Italy | 4 | 2019 | 116 | 0.070 |
Why?
| | Receptors, Mineralocorticoid | 1 | 2009 | 11 | 0.070 |
Why?
| | Morphine | 1 | 2010 | 168 | 0.070 |
Why?
| | Logistic Models | 3 | 2010 | 2134 | 0.070 |
Why?
| | Molecular Sequence Data | 6 | 2015 | 2883 | 0.070 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 1963 | 0.070 |
Why?
| | United States | 4 | 2022 | 16098 | 0.070 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2010 | 194 | 0.070 |
Why?
| | NF-kappa B | 2 | 2025 | 666 | 0.070 |
Why?
| | Inflammation Mediators | 2 | 2024 | 506 | 0.070 |
Why?
| | Neoplasms | 2 | 2022 | 2906 | 0.070 |
Why?
| | Cyclooxygenase 2 | 2 | 2019 | 166 | 0.070 |
Why?
| | RANK Ligand | 1 | 2008 | 27 | 0.070 |
Why?
| | Liver Neoplasms | 1 | 2015 | 776 | 0.070 |
Why?
| | Iohexol | 1 | 2008 | 23 | 0.070 |
Why?
| | Aorta, Abdominal | 1 | 2008 | 52 | 0.070 |
Why?
| | Radiographic Image Enhancement | 1 | 2008 | 57 | 0.070 |
Why?
| | Breeding | 2 | 2014 | 63 | 0.070 |
Why?
| | Blood Platelets | 1 | 2011 | 379 | 0.070 |
Why?
| | Receptors, Glucocorticoid | 1 | 2009 | 129 | 0.070 |
Why?
| | Androgens | 1 | 2009 | 181 | 0.070 |
Why?
| | Scleroderma, Systemic | 1 | 2008 | 123 | 0.070 |
Why?
| | Young Adult | 6 | 2024 | 14218 | 0.070 |
Why?
| | Alanine Transaminase | 2 | 2019 | 151 | 0.060 |
Why?
| | Nutritional Physiological Phenomena | 1 | 2007 | 57 | 0.060 |
Why?
| | Adrenocorticotropic Hormone | 3 | 2017 | 147 | 0.060 |
Why?
| | Computer-Assisted Instruction | 1 | 2008 | 70 | 0.060 |
Why?
| | Observer Variation | 1 | 2008 | 357 | 0.060 |
Why?
| | Electronic Mail | 1 | 2007 | 60 | 0.060 |
Why?
| | Mutation | 3 | 2017 | 4075 | 0.060 |
Why?
| | Vagina | 2 | 2020 | 203 | 0.060 |
Why?
| | Hepatic Encephalopathy | 1 | 2007 | 25 | 0.060 |
Why?
| | Membrane Proteins | 1 | 1993 | 1164 | 0.060 |
Why?
| | Alcohol Dehydrogenase | 1 | 2006 | 16 | 0.060 |
Why?
| | Aortic Aneurysm, Abdominal | 1 | 2008 | 167 | 0.060 |
Why?
| | Adrenal Cortex | 1 | 2006 | 33 | 0.060 |
Why?
| | Ovarian Neoplasms | 1 | 2012 | 595 | 0.060 |
Why?
| | Superoxide Dismutase | 2 | 2019 | 308 | 0.060 |
Why?
| | Cytokine Receptor gp130 | 1 | 2006 | 11 | 0.060 |
Why?
| | Adolescent | 8 | 2020 | 22529 | 0.060 |
Why?
| | Computer Simulation | 2 | 2023 | 1003 | 0.060 |
Why?
| | Cecum | 1 | 2026 | 37 | 0.060 |
Why?
| | False Positive Reactions | 1 | 2026 | 123 | 0.060 |
Why?
| | Pentacyclic Triterpenes | 1 | 2026 | 12 | 0.060 |
Why?
| | Up-Regulation | 2 | 2019 | 847 | 0.060 |
Why?
| | Brain Chemistry | 2 | 2009 | 119 | 0.060 |
Why?
| | Prednisolone | 1 | 2006 | 67 | 0.060 |
Why?
| | Receptors, Interleukin-6 | 1 | 2006 | 48 | 0.060 |
Why?
| | Health Planning Guidelines | 1 | 2006 | 24 | 0.060 |
Why?
| | Solitary Nucleus | 1 | 2026 | 25 | 0.060 |
Why?
| | Aldehyde Dehydrogenase | 1 | 2006 | 99 | 0.060 |
Why?
| | Heart Defects, Congenital | 1 | 2014 | 910 | 0.060 |
Why?
| | Culture | 1 | 2006 | 124 | 0.060 |
Why?
| | Australia | 1 | 2006 | 288 | 0.060 |
Why?
| | Self Administration | 1 | 2026 | 122 | 0.060 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2006 | 161 | 0.060 |
Why?
| | Bone Resorption | 1 | 2006 | 81 | 0.060 |
Why?
| | Program Evaluation | 2 | 2007 | 943 | 0.060 |
Why?
| | Alleles | 2 | 2019 | 894 | 0.060 |
Why?
| | Vagus Nerve | 1 | 2026 | 92 | 0.060 |
Why?
| | Muscle Fatigue | 1 | 2006 | 98 | 0.060 |
Why?
| | Spheroids, Cellular | 1 | 2026 | 74 | 0.060 |
Why?
| | HIV Infections | 1 | 2020 | 3193 | 0.050 |
Why?
| | Phosphorylation | 2 | 2019 | 1707 | 0.050 |
Why?
| | Germ-Free Life | 1 | 2025 | 33 | 0.050 |
Why?
| | Cells, Cultured | 3 | 2021 | 4148 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2006 | 412 | 0.050 |
Why?
| | Ultraviolet Rays | 1 | 2008 | 384 | 0.050 |
Why?
| | Rats, Sprague-Dawley | 2 | 2020 | 2524 | 0.050 |
Why?
| | Predictive Value of Tests | 3 | 2020 | 2121 | 0.050 |
Why?
| | Health Promotion | 2 | 2008 | 775 | 0.050 |
Why?
| | Schools | 1 | 2008 | 448 | 0.050 |
Why?
| | Elective Surgical Procedures | 1 | 2006 | 202 | 0.050 |
Why?
| | Pregnancy | 4 | 2022 | 7202 | 0.050 |
Why?
| | Acetylation | 1 | 2024 | 259 | 0.050 |
Why?
| | Sports | 1 | 2006 | 211 | 0.050 |
Why?
| | Molecular Sequence Annotation | 1 | 2024 | 105 | 0.050 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2008 | 779 | 0.050 |
Why?
| | Lung Neoplasms | 1 | 2017 | 2664 | 0.050 |
Why?
| | Case-Control Studies | 4 | 2017 | 3623 | 0.050 |
Why?
| | Cystic Fibrosis | 1 | 1993 | 1161 | 0.050 |
Why?
| | Arthroplasty, Replacement, Hip | 1 | 2006 | 182 | 0.050 |
Why?
| | Albumins | 1 | 2023 | 119 | 0.050 |
Why?
| | Survival Rate | 2 | 2019 | 2090 | 0.050 |
Why?
| | Actin Cytoskeleton | 1 | 2024 | 103 | 0.050 |
Why?
| | Environmental Exposure | 1 | 2008 | 578 | 0.050 |
Why?
| | Trastuzumab | 1 | 2023 | 118 | 0.050 |
Why?
| | Plant Extracts | 1 | 2025 | 188 | 0.050 |
Why?
| | Transforming Growth Factor beta | 1 | 2025 | 474 | 0.050 |
Why?
| | Leptin | 1 | 2004 | 248 | 0.050 |
Why?
| | Risk Assessment | 1 | 2012 | 3747 | 0.050 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2025 | 507 | 0.050 |
Why?
| | Flow Cytometry | 1 | 2026 | 1162 | 0.050 |
Why?
| | Microarray Analysis | 2 | 2015 | 116 | 0.050 |
Why?
| | Prospective Studies | 4 | 2020 | 8057 | 0.040 |
Why?
| | Prostatic Neoplasms | 1 | 2009 | 978 | 0.040 |
Why?
| | Health Behavior | 1 | 2007 | 789 | 0.040 |
Why?
| | Epigenomics | 1 | 2022 | 114 | 0.040 |
Why?
| | Patient Compliance | 1 | 2006 | 587 | 0.040 |
Why?
| | Actins | 1 | 2024 | 425 | 0.040 |
Why?
| | Odds Ratio | 2 | 2020 | 1082 | 0.040 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2011 | 848 | 0.040 |
Why?
| | Amino Acid Sequence | 2 | 2020 | 2129 | 0.040 |
Why?
| | Mass Screening | 2 | 2010 | 1360 | 0.040 |
Why?
| | Blotting, Western | 2 | 2015 | 1179 | 0.040 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2008 | 1419 | 0.040 |
Why?
| | Rats, Inbred Lew | 1 | 2001 | 105 | 0.040 |
Why?
| | Iodine | 1 | 2021 | 27 | 0.040 |
Why?
| | Photoreceptor Cells, Invertebrate | 1 | 2020 | 4 | 0.040 |
Why?
| | Pharmacogenomic Testing | 1 | 2021 | 63 | 0.040 |
Why?
| | Killer Cells, Natural | 1 | 2004 | 480 | 0.040 |
Why?
| | DNA, Complementary | 1 | 2001 | 273 | 0.040 |
Why?
| | Rats, Inbred F344 | 1 | 2001 | 268 | 0.040 |
Why?
| | Indians, North American | 1 | 2006 | 597 | 0.040 |
Why?
| | Treatment Outcome | 3 | 2017 | 11772 | 0.040 |
Why?
| | Curriculum | 1 | 2008 | 1070 | 0.040 |
Why?
| | Time Factors | 4 | 2019 | 7123 | 0.040 |
Why?
| | Oxysterols | 1 | 2020 | 2 | 0.040 |
Why?
| | Multiple Sclerosis | 1 | 2006 | 489 | 0.040 |
Why?
| | Cannabinoid Receptor Agonists | 1 | 2020 | 44 | 0.040 |
Why?
| | Cytomegalovirus | 1 | 2021 | 168 | 0.040 |
Why?
| | Carcinogenesis | 1 | 2022 | 228 | 0.040 |
Why?
| | Magnetic Resonance Angiography | 1 | 2022 | 251 | 0.040 |
Why?
| | Kainic Acid | 1 | 2020 | 33 | 0.040 |
Why?
| | Carbon | 1 | 2021 | 176 | 0.040 |
Why?
| | Monte Carlo Method | 1 | 2020 | 147 | 0.040 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2020 | 74 | 0.040 |
Why?
| | DNA Primers | 1 | 2001 | 505 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2006 | 1747 | 0.040 |
Why?
| | Catheterization | 1 | 2000 | 183 | 0.040 |
Why?
| | Aspartate Aminotransferases | 1 | 2019 | 85 | 0.040 |
Why?
| | Protective Agents | 1 | 2019 | 42 | 0.040 |
Why?
| | Blood Pressure Monitoring, Ambulatory | 1 | 2020 | 69 | 0.040 |
Why?
| | Infant, Newborn | 2 | 2022 | 6447 | 0.040 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2019 | 153 | 0.040 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2019 | 88 | 0.040 |
Why?
| | Heme Oxygenase-1 | 1 | 2019 | 76 | 0.040 |
Why?
| | Urinary Bladder Diseases | 1 | 2019 | 18 | 0.040 |
Why?
| | Metabolic Syndrome | 2 | 2017 | 360 | 0.040 |
Why?
| | Lipid Peroxidation | 1 | 2019 | 167 | 0.040 |
Why?
| | Transplant Recipients | 1 | 2021 | 181 | 0.040 |
Why?
| | Benchmarking | 1 | 2020 | 191 | 0.040 |
Why?
| | Hedgehog Proteins | 1 | 2020 | 200 | 0.040 |
Why?
| | Sample Size | 1 | 2019 | 121 | 0.040 |
Why?
| | Emtricitabine | 1 | 2020 | 210 | 0.040 |
Why?
| | Group IV Phospholipases A2 | 1 | 2019 | 46 | 0.040 |
Why?
| | Biological Transport | 1 | 2020 | 424 | 0.040 |
Why?
| | Bacteria | 1 | 2025 | 765 | 0.040 |
Why?
| | Sensation | 1 | 1999 | 55 | 0.040 |
Why?
| | Cerebellum | 1 | 2001 | 224 | 0.040 |
Why?
| | Education | 1 | 2019 | 104 | 0.040 |
Why?
| | Muscle, Skeletal | 2 | 2006 | 1789 | 0.040 |
Why?
| | Substance Abuse Detection | 1 | 2020 | 110 | 0.040 |
Why?
| | Birth Weight | 1 | 2022 | 514 | 0.040 |
Why?
| | Caspase 3 | 1 | 2019 | 242 | 0.040 |
Why?
| | Molecular Weight | 1 | 2019 | 312 | 0.040 |
Why?
| | Colitis, Ulcerative | 1 | 2000 | 148 | 0.040 |
Why?
| | Lysosomes | 1 | 2019 | 131 | 0.040 |
Why?
| | Normal Distribution | 1 | 2018 | 22 | 0.040 |
Why?
| | Pulmonary Circulation | 1 | 2021 | 430 | 0.040 |
Why?
| | Urogenital Abnormalities | 1 | 2019 | 71 | 0.040 |
Why?
| | Ligaments | 1 | 2019 | 76 | 0.040 |
Why?
| | Protons | 1 | 2019 | 96 | 0.040 |
Why?
| | Absorptiometry, Photon | 2 | 2012 | 277 | 0.030 |
Why?
| | Rats, Transgenic | 1 | 2018 | 20 | 0.030 |
Why?
| | Sirtuins | 1 | 2019 | 50 | 0.030 |
Why?
| | Metyrapone | 1 | 2018 | 5 | 0.030 |
Why?
| | Neuroimaging | 1 | 2021 | 297 | 0.030 |
Why?
| | Receptors, AMPA | 1 | 2020 | 147 | 0.030 |
Why?
| | Colorado | 3 | 2020 | 4553 | 0.030 |
Why?
| | Age of Onset | 1 | 2020 | 555 | 0.030 |
Why?
| | GABA-A Receptor Antagonists | 1 | 2018 | 19 | 0.030 |
Why?
| | Computer Graphics | 1 | 2018 | 41 | 0.030 |
Why?
| | Dinitrobenzenes | 1 | 2018 | 5 | 0.030 |
Why?
| | Fluorescent Dyes | 1 | 2020 | 333 | 0.030 |
Why?
| | Mice, 129 Strain | 1 | 2018 | 84 | 0.030 |
Why?
| | Sirtuin 3 | 1 | 2019 | 60 | 0.030 |
Why?
| | Analgesics | 1 | 2020 | 231 | 0.030 |
Why?
| | Cardiovascular Diseases | 2 | 2008 | 2187 | 0.030 |
Why?
| | Receptors, IgE | 1 | 2018 | 43 | 0.030 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2019 | 264 | 0.030 |
Why?
| | Metabolic Networks and Pathways | 1 | 2019 | 174 | 0.030 |
Why?
| | Rectum | 1 | 2019 | 182 | 0.030 |
Why?
| | Uterus | 1 | 2019 | 227 | 0.030 |
Why?
| | Ribosomes | 1 | 2019 | 193 | 0.030 |
Why?
| | Abdominal Pain | 1 | 1999 | 149 | 0.030 |
Why?
| | Magnetite Nanoparticles | 1 | 2017 | 27 | 0.030 |
Why?
| | Thioredoxins | 1 | 2017 | 30 | 0.030 |
Why?
| | Azo Compounds | 1 | 2017 | 30 | 0.030 |
Why?
| | Enzyme Activation | 1 | 2019 | 762 | 0.030 |
Why?
| | Organ Specificity | 1 | 2018 | 309 | 0.030 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2017 | 75 | 0.030 |
Why?
| | Crigler-Najjar Syndrome | 1 | 1997 | 2 | 0.030 |
Why?
| | Dronabinol | 1 | 2020 | 249 | 0.030 |
Why?
| | Protein Structure, Secondary | 1 | 2018 | 371 | 0.030 |
Why?
| | Metal Nanoparticles | 1 | 2018 | 80 | 0.030 |
Why?
| | Heterozygote | 3 | 1994 | 313 | 0.030 |
Why?
| | Glucuronosyltransferase | 1 | 1997 | 18 | 0.030 |
Why?
| | Tuberculosis | 1 | 2020 | 283 | 0.030 |
Why?
| | Solubility | 2 | 2008 | 240 | 0.030 |
Why?
| | Biomarkers, Tumor | 1 | 2024 | 1321 | 0.030 |
Why?
| | Cell Survival | 1 | 2020 | 1100 | 0.030 |
Why?
| | DNA Damage | 1 | 2019 | 437 | 0.030 |
Why?
| | Drug Delivery Systems | 1 | 2020 | 381 | 0.030 |
Why?
| | Surface Properties | 1 | 2017 | 386 | 0.030 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2017 | 178 | 0.030 |
Why?
| | Medication Adherence | 1 | 2020 | 540 | 0.030 |
Why?
| | Exons | 2 | 1997 | 363 | 0.030 |
Why?
| | Genetic Linkage | 2 | 2007 | 272 | 0.030 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 1 | 2018 | 228 | 0.030 |
Why?
| | Metabolome | 1 | 2019 | 388 | 0.030 |
Why?
| | Genotyping Techniques | 1 | 2016 | 71 | 0.030 |
Why?
| | Hospital Mortality | 1 | 2021 | 1038 | 0.030 |
Why?
| | Lipogenesis | 1 | 2016 | 62 | 0.030 |
Why?
| | Respiration, Artificial | 1 | 2021 | 713 | 0.030 |
Why?
| | Fatty Acids, Unsaturated | 1 | 2016 | 96 | 0.030 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2019 | 534 | 0.030 |
Why?
| | Autophagy | 1 | 2018 | 291 | 0.030 |
Why?
| | Iopamidol | 1 | 2015 | 12 | 0.030 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2018 | 196 | 0.030 |
Why?
| | Postoperative Complications | 1 | 2008 | 2970 | 0.030 |
Why?
| | Animals, Inbred Strains | 1 | 2015 | 6 | 0.030 |
Why?
| | Glomerular Filtration Rate | 1 | 2019 | 765 | 0.030 |
Why?
| | Lipids | 1 | 2020 | 707 | 0.030 |
Why?
| | Child | 4 | 2014 | 22707 | 0.030 |
Why?
| | Aryl Hydrocarbon Receptor Nuclear Translocator | 1 | 2015 | 19 | 0.030 |
Why?
| | Length of Stay | 1 | 2021 | 1349 | 0.030 |
Why?
| | Codon | 2 | 1992 | 92 | 0.030 |
Why?
| | Heart | 1 | 2018 | 626 | 0.030 |
Why?
| | Linear Models | 1 | 2017 | 845 | 0.030 |
Why?
| | Genetic Testing | 1 | 1997 | 480 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2019 | 892 | 0.030 |
Why?
| | Principal Component Analysis | 1 | 2015 | 193 | 0.030 |
Why?
| | Glutathione | 1 | 2016 | 370 | 0.030 |
Why?
| | Histones | 1 | 2019 | 666 | 0.030 |
Why?
| | Protein Isoforms | 1 | 2015 | 397 | 0.030 |
Why?
| | Gene Deletion | 1 | 2015 | 391 | 0.030 |
Why?
| | Gene Frequency | 1 | 2015 | 487 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2016 | 440 | 0.030 |
Why?
| | Saliva | 2 | 2006 | 246 | 0.030 |
Why?
| | Triglycerides | 1 | 2016 | 520 | 0.030 |
Why?
| | Prevalence | 1 | 2021 | 2865 | 0.020 |
Why?
| | Radiation Dosage | 1 | 2015 | 193 | 0.020 |
Why?
| | Chelation Therapy | 1 | 2013 | 10 | 0.020 |
Why?
| | Iron Chelating Agents | 1 | 2013 | 17 | 0.020 |
Why?
| | Chronic Disease | 1 | 2019 | 1808 | 0.020 |
Why?
| | Cell Line | 1 | 2019 | 2823 | 0.020 |
Why?
| | Carrier Proteins | 1 | 2017 | 728 | 0.020 |
Why?
| | Mice, Transgenic | 2 | 2010 | 2188 | 0.020 |
Why?
| | Ovarian Diseases | 1 | 2012 | 14 | 0.020 |
Why?
| | Entropy | 1 | 2012 | 44 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2020 | 2046 | 0.020 |
Why?
| | Protein Binding | 1 | 2019 | 2238 | 0.020 |
Why?
| | Databases, Factual | 1 | 2018 | 1490 | 0.020 |
Why?
| | Thalassemia | 1 | 1992 | 6 | 0.020 |
Why?
| | Glucose | 1 | 2017 | 1048 | 0.020 |
Why?
| | Exome | 1 | 2013 | 227 | 0.020 |
Why?
| | Ultrasonography, Doppler | 1 | 2012 | 126 | 0.020 |
Why?
| | Surveys and Questionnaires | 2 | 2022 | 6066 | 0.020 |
Why?
| | Data Mining | 1 | 2012 | 113 | 0.020 |
Why?
| | Blood Cell Count | 1 | 2011 | 55 | 0.020 |
Why?
| | Transferrin | 1 | 2011 | 50 | 0.020 |
Why?
| | DNA | 3 | 1994 | 1435 | 0.020 |
Why?
| | Models, Biological | 1 | 2019 | 1764 | 0.020 |
Why?
| | Liver Function Tests | 1 | 2011 | 105 | 0.020 |
Why?
| | Reference Standards | 1 | 2011 | 177 | 0.020 |
Why?
| | Placenta | 1 | 2018 | 786 | 0.020 |
Why?
| | Genetics, Behavioral | 1 | 2010 | 17 | 0.020 |
Why?
| | Clinical Competence | 1 | 2019 | 1243 | 0.020 |
Why?
| | Thermosensing | 1 | 2010 | 12 | 0.020 |
Why?
| | Haplotypes | 1 | 2012 | 499 | 0.020 |
Why?
| | Ovary | 1 | 2012 | 233 | 0.020 |
Why?
| | Software Design | 1 | 2010 | 25 | 0.020 |
Why?
| | Crosses, Genetic | 1 | 2010 | 123 | 0.020 |
Why?
| | Neurons | 1 | 2020 | 1649 | 0.020 |
Why?
| | Obesity | 1 | 2004 | 3116 | 0.020 |
Why?
| | Diagnostic and Statistical Manual of Mental Disorders | 1 | 2011 | 231 | 0.020 |
Why?
| | Antisocial Personality Disorder | 1 | 2011 | 121 | 0.020 |
Why?
| | Contraindications | 1 | 2010 | 90 | 0.020 |
Why?
| | Asymptomatic Diseases | 1 | 2010 | 104 | 0.020 |
Why?
| | Immunoblotting | 1 | 2010 | 295 | 0.020 |
Why?
| | Blood Proteins | 1 | 2011 | 239 | 0.020 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 1993 | 371 | 0.020 |
Why?
| | 11-beta-Hydroxysteroid Dehydrogenase Type 1 | 1 | 2009 | 10 | 0.020 |
Why?
| | 11-beta-Hydroxysteroid Dehydrogenase Type 2 | 1 | 2009 | 10 | 0.020 |
Why?
| | Adrenal Gland Neoplasms | 1 | 2010 | 98 | 0.020 |
Why?
| | Corticosterone | 1 | 2010 | 241 | 0.020 |
Why?
| | Vascular Cell Adhesion Molecule-1 | 1 | 2008 | 42 | 0.020 |
Why?
| | Sex Factors | 1 | 2015 | 2105 | 0.020 |
Why?
| | Mice, Inbred CBA | 1 | 2008 | 57 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2012 | 1508 | 0.020 |
Why?
| | New Mexico | 1 | 2008 | 99 | 0.020 |
Why?
| | Social Marketing | 1 | 2008 | 15 | 0.020 |
Why?
| | Mice, Inbred C3H | 1 | 2008 | 254 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 977 | 0.020 |
Why?
| | Rural Health | 1 | 2008 | 87 | 0.020 |
Why?
| | Meta-Analysis as Topic | 1 | 2008 | 171 | 0.020 |
Why?
| | Brain Mapping | 1 | 2010 | 538 | 0.020 |
Why?
| | Pituitary Function Tests | 1 | 2007 | 2 | 0.020 |
Why?
| | Receptor Activator of Nuclear Factor-kappa B | 1 | 2007 | 9 | 0.020 |
Why?
| | Fruit | 1 | 2008 | 146 | 0.020 |
Why?
| | Sunlight | 1 | 2008 | 78 | 0.020 |
Why?
| | Vegetables | 1 | 2008 | 161 | 0.020 |
Why?
| | Interleukin-1beta | 1 | 2009 | 389 | 0.020 |
Why?
| | Aldehyde Dehydrogenase, Mitochondrial | 1 | 2006 | 23 | 0.020 |
Why?
| | Myoglobin | 1 | 2006 | 12 | 0.020 |
Why?
| | Stochastic Processes | 1 | 2007 | 65 | 0.020 |
Why?
| | Acetaldehyde | 1 | 2006 | 17 | 0.020 |
Why?
| | Retinal Dehydrogenase | 1 | 2006 | 29 | 0.020 |
Why?
| | Adrenal Glands | 1 | 2007 | 76 | 0.020 |
Why?
| | Genetic Carrier Screening | 2 | 1997 | 32 | 0.020 |
Why?
| | Pituitary Gland | 1 | 2007 | 149 | 0.010 |
Why?
| | Reminder Systems | 1 | 2007 | 140 | 0.010 |
Why?
| | Electrophysiology | 1 | 2006 | 218 | 0.010 |
Why?
| | Osteoclasts | 1 | 2006 | 54 | 0.010 |
Why?
| | Injections, Intravenous | 1 | 2006 | 197 | 0.010 |
Why?
| | Hip Prosthesis | 1 | 2006 | 42 | 0.010 |
Why?
| | Hormones | 1 | 2006 | 135 | 0.010 |
Why?
| | Bone and Bones | 1 | 2008 | 317 | 0.010 |
Why?
| | Educational Status | 1 | 2008 | 466 | 0.010 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2006 | 267 | 0.010 |
Why?
| | Muscle Fibers, Skeletal | 1 | 2006 | 212 | 0.010 |
Why?
| | Lactic Acid | 1 | 2006 | 295 | 0.010 |
Why?
| | Physical Endurance | 1 | 2006 | 279 | 0.010 |
Why?
| | Pedigree | 2 | 1997 | 515 | 0.010 |
Why?
| | Educational Measurement | 1 | 2008 | 326 | 0.010 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2004 | 61 | 0.010 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 2004 | 89 | 0.010 |
Why?
| | Confidence Intervals | 1 | 2004 | 330 | 0.010 |
Why?
| | Electromyography | 1 | 2006 | 419 | 0.010 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2004 | 224 | 0.010 |
Why?
| | Anthropometry | 1 | 2004 | 206 | 0.010 |
Why?
| | Dietary Carbohydrates | 1 | 2004 | 147 | 0.010 |
Why?
| | Interleukin-2 | 1 | 2004 | 440 | 0.010 |
Why?
| | Biomechanical Phenomena | 1 | 2006 | 857 | 0.010 |
Why?
| | Vitamin D | 1 | 2006 | 403 | 0.010 |
Why?
| | Dietary Fats | 1 | 2004 | 308 | 0.010 |
Why?
| | Cohort Studies | 1 | 2012 | 6013 | 0.010 |
Why?
| | Neoplasm Staging | 1 | 2004 | 1471 | 0.010 |
Why?
| | Patient Selection | 1 | 2004 | 738 | 0.010 |
Why?
| | Skin Neoplasms | 1 | 2008 | 849 | 0.010 |
Why?
| | Viscera | 1 | 1999 | 17 | 0.010 |
Why?
| | Patient Acceptance of Health Care | 1 | 2006 | 881 | 0.010 |
Why?
| | Research Design | 1 | 2004 | 1137 | 0.010 |
Why?
| | Psychological Tests | 1 | 1999 | 130 | 0.010 |
Why?
| | Age Factors | 1 | 2006 | 3342 | 0.010 |
Why?
| | Cytokines | 1 | 2006 | 2067 | 0.010 |
Why?
| | Child, Preschool | 2 | 2008 | 11853 | 0.010 |
Why?
| | Pain Measurement | 1 | 2000 | 561 | 0.010 |
Why?
| | Perception | 1 | 2000 | 378 | 0.010 |
Why?
| | Genetics, Population | 1 | 1997 | 217 | 0.010 |
Why?
| | Prenatal Diagnosis | 1 | 1997 | 196 | 0.010 |
Why?
| | Registries | 1 | 2004 | 2406 | 0.010 |
Why?
| | Body Mass Index | 1 | 2004 | 2445 | 0.010 |
Why?
| | Homozygote | 1 | 1994 | 199 | 0.010 |
Why?
| | Frameshift Mutation | 1 | 1992 | 31 | 0.010 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1992 | 331 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 1992 | 1041 | 0.000 |
Why?
| | Infant | 1 | 1997 | 10077 | 0.000 |
Why?
|
|
Saba's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|